Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373797 | 0.87 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL10040947 | 0.86 | TGFBR1 (0.75) | TGFBR1 | |
| SCHEMBL4032177 | 0.85 | TGFBR1 (0.75) | TGFBR1MAPK14THRB | |
| SCHEMBL373438 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL31060282 | 0.79 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL4030536 | 0.78 | TGFBR1 (0.66) | TGFBR1MAPK14THRB | |
| Gw693481X SCHEMBL373662 | 0.77 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL31061458 | 0.76 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL31060753 | 0.75 | TGFBR1 (0.60) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL6627903 | 0.75 | TGFBR1 (0.67) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063745-A1 | 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-01 | — | — | US | claimed |
| EP-1355892-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002062776-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20040063745-A1 | 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1355892-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062776-A1 | 2-AMINO-4-(PYRIDIN-2-YL)-THIAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR BETA (TGF-BETA) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063745-A1 | 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885MAPK14 3047/4885TGFBR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.